NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ITOS

ITeos Therapeutics Inc

Jun 30 • 04:00PM ET

9.97

Dollar change +0.02
Percentage change 0.20	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA AZN BMY GILD AMGN PFE JNJ REGN VRTX INCY

| Held by: VTI IWM VXF IWN IBB DFAT VTWO SCHA VHT AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.23	Insider Own	6.26%	Shs Outstand	38.27M	Perf Week	-1.38%
Market Cap	381.59M	Forward P/E	-	EPS next Y	-1.57	Insider Trans	-	Shs Float	35.88M	Perf Month	-0.60%
Enterprise Value	-133.73M	PEG	-	EPS next Q	-0.89	Inst Own	116.81%	Short Float	7.53%	Perf Quarter	57.75%
Income	-130.81M	P/S	10.90	EPS this Y	15.74%	Inst Trans	32.20%	Short Ratio	2.02	Perf Half Y	33.47%
Sales	35.00M	P/B	0.68	EPS next Y	44.03%	ROA	-20.30%	Short Interest	2.70M	Perf YTD	29.82%
Book/sh	14.72	P/C	0.73	EPS next 5Y	3.89%	ROE	-23.68%	52W High	18.13 -45.01%	Perf Year	-33.71%
Cash/sh	13.60	P/FCF	-	EPS past 3/5Y	- -34.39%	ROIC	-23.07%	52W Low	4.80 107.71%	Perf 3Y	-53.69%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-53.35% -	Gross Margin	96.41%	Volatility	1.27% 1.78%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-3.82	EPS Y/Y TTM	14.60%	Oper. Margin	-435.19%	ATR (14)	0.27	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.13	Sales Y/Y TTM	177.89%	Profit Margin	-373.75%	RSI (14)	62.72	Recom	2.67
Dividend Gr. 3/5Y	- -	Current Ratio	14.13	EPS Q/Q	24.92%	SMA20	-0.87%	Beta	1.50	Target Price	12.83
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	15.19%	Rel Volume	0.53	Prev Close	9.95
Employees	173	LT Debt/Eq	0.01	Earnings	Apr 28 AMC	SMA200	20.17%	Avg Volume	1.33M	Price	9.97
IPO	Jul 24, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.79% -100.00%	Trades		Volume	702,082	Change	0.20%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$12
May-28-25	Downgrade	Wedbush	Outperform → Neutral	$12
May-14-25	Downgrade	Leerink Partners	Outperform → Market Perform	$9
May-14-25	Downgrade	H.C. Wainwright	Buy → Neutral
May-13-25	Downgrade	JP Morgan	Overweight → Neutral
Aug-13-24	Initiated	Wells Fargo	Overweight	$31
May-05-21	Initiated	H.C. Wainwright	Buy	$37
Oct-08-20	Initiated	Robert W. Baird	Outperform	$45
Aug-18-20	Initiated	Wedbush	Outperform	$45
Aug-18-20	Initiated	SVB Leerink	Outperform	$45
Aug-18-20	Initiated	Piper Sandler	Overweight	$50
Aug-18-20	Initiated	JP Morgan	Overweight	$40

Show Previous Ratings

May-30-25 12:00PM	iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know (Zacks)
May-29-25 07:59AM	iTeos to shut down following $2bn GSK-partnered TIGIT asset failure (Pharmaceutical Technology)
May-28-25 08:30AM	iTeos Therapeutics Announces Its Intention to Wind Down Operations (GlobeNewswire) +17.94%
08:10AM	Cancer drugmaker iTeos to shut down (BioPharma Dive)
May-15-25 07:55AM	GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug (Zacks)
06:00AM	Loading…
May-14-25 06:00AM	GSK and iTeos drop anti-TIGIT drug following trial failure (Clinical Trials Arena)
May-13-25 12:35PM	iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile (Benzinga) +13.44%
07:55AM	iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients (GlobeNewswire)
07:10AM	iTeos, GSK to shelve TIGIT drug after study setback (BioPharma Dive)
May-02-25 09:55AM	Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High? (Zacks)
Apr-28-25 04:30PM	iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-25-25 04:35PM	iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 (GlobeNewswire) -5.44%
Mar-13-25 09:55AM	Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet (Zacks)
Mar-05-25 07:00AM	iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire) +5.99%
Jan-13-25 12:00PM	All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy (Zacks)
07:00AM	Loading…
Jan-10-25 07:00AM	iTeos Announces 2025 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Jan-08-25 07:00AM	iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-24 07:20AM	iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo (TipRanks)
Dec-13-24 01:25PM	Inupadenant deprioritised by iTeos in favour of pipeline TIGIT therapy (Clinical Trials Arena)
Dec-12-24 08:55AM	iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress (GlobeNewswire)
Nov-26-24 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 07:00AM	iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-24-24 07:00AM	iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress (GlobeNewswire)
Oct-16-24 01:01AM	BOXER CAPITAL, LLC Expands Stake in ITeos Therapeutics Inc (GuruFocus.com)
Sep-30-24 01:01PM	TANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeutics Inc (GuruFocus.com)
Sep-16-24 04:04PM	Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths (Investor's Business Daily) -27.54%
Sep-15-24 09:12PM	ESMO 2024: TIGIT race tightens with first look at GSK/iTeoss TIGIT in NSCLC (Pharmaceutical Technology)
Sep-14-24 08:10AM	TIGIT drug from iTeos shrinks lung tumors in trial (BioPharma Dive)
02:30AM	iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients (GlobeNewswire)
Aug-28-24 04:30PM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:30AM	Loading…
Aug-20-24 08:30AM	iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024 (GlobeNewswire) +10.13%
Aug-08-24 08:20AM	ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-05-24 07:00AM	iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer (GlobeNewswire)
Jul-09-24 12:33PM	iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial (Pharmaceutical Technology)
Jul-08-24 07:00AM	iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK (GlobeNewswire)
Jun-18-24 06:33AM	iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC (Clinical Trials Arena)
Jun-17-24 09:00AM	iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer (GlobeNewswire) -6.04%
May-13-24 08:28AM	HC Wainwright Adjusts Price Target on iTeos Therapeutics to $46 From $44, Maintains Buy Rating (MT Newswires)
May-10-24 01:53PM	ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +43.07%
12:21PM	Wedbush Adjusts iTeos Therapeutics' Price Target to $21 From $18, Maintains Outperform Rating (MT Newswires)
09:40AM	iTeos Therapeutics Q1 Net Loss Widens; Initiates $120 Million Registered Direct Offering -- Shares Jump (MT Newswires)
08:26AM	iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
08:24AM	iTeos Therapeutics Announces $120 Million Registered Direct Offering (GlobeNewswire)
08:09AM	iTeos shares jump on TIGIT update; Acelyrin swaps CEOs (BioPharma Dive)
Apr-07-24 04:30PM	iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-06-24 02:51PM	ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +7.80%
07:01AM	iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors (GlobeNewswire)
07:00AM	iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-24 04:30PM	iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-01-24 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.23%
Feb-26-24 06:11AM	Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength? (Zacks)
Jan-08-24 07:00AM	iTeos Announces 2024 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Jan-03-24 07:00AM	iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-13-23 09:55AM	Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to Trade (Zacks)
Nov-27-23 09:55AM	Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect? (Zacks) -5.44%
Nov-21-23 07:00AM	iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-13-23 09:55AM	Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher (Zacks)
Nov-10-23 09:55AM	Wall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should Know (Zacks)
Nov-07-23 07:00AM	iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-31-23 03:01AM	Viridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar? (Zacks) +7.48%
Oct-16-23 01:46PM	Hedge Fund and Insider Trading News: Ken Griffin, EcoR1 Capital, Glen Point Capital, JAT Capital, Eisler Capital, Elliott Management, iTeos Therapeutics Inc (ITOS), Funko, Inc. (FNKO), and More (Insider Monkey)
04:38AM	iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar? (Zacks)
Oct-11-23 05:55PM	NCR Atleos Set to Join S&P SmallCap 600 (PR Newswire) -6.72% -6.39%
Sep-06-23 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-23 11:02AM	BOXER CAPITAL, LLC Reduces Stake in ITeos Therapeutics Inc (GuruFocus.com)
Aug-24-23 11:30AM	Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak (Zacks)
Aug-23-23 04:10PM	Why Roche's Accidental Cancer Update Boosted Several Rivals By As Much As 22% (Investor's Business Daily) +14.89%
02:00PM	Watertown biotech shares spike after accidental data publication at Roche (American City Business Journals)
09:24AM	How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30% (Investor's Business Daily)
Aug-08-23 07:00AM	iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jun-21-23 08:00PM	ITOS: Lowering target price to $11.00 (Argus Research)
May-13-23 08:03AM	Broker Revenue Forecasts For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Are Surging Higher (Simply Wall St.)
May-11-23 06:11AM	iTeos Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-10-23 08:35AM	ITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:01AM	iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
May-05-23 08:51AM	iTeos Therapeutics (NASDAQ:ITOS) shareholders have endured a 46% loss from investing in the stock a year ago (Simply Wall St.)
Apr-26-23 08:00PM	ITOS: What does Argus have to say about ITOS? (Argus Research)
Mar-23-23 01:56PM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks)
Mar-21-23 06:07AM	Take Care Before Jumping Onto iTeos Therapeutics, Inc. (NASDAQ:ITOS) Even Though It's 25% Cheaper (Simply Wall St.)
Mar-17-23 06:18AM	Time To Worry? Analysts Are Downgrading Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Outlook (Simply Wall St.)
Mar-15-23 08:35AM	ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:00AM	iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-28-23 07:00AM	iTeos to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-07-23 01:51PM	The 7 Best Biotech Stocks to Buy for February 2023 (InvestorPlace)
07:00AM	iTeos to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-02-23 02:19PM	The 7 Most Undervalued Biotech Stocks to Buy in February 2023 (InvestorPlace)
Jan-09-23 07:00AM	iTeos Provides Business Updates and Clinical Development Plans for 2023 (GlobeNewswire)
Jan-03-23 07:00AM	iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.07%
Dec-07-22 08:07AM	Could The Market Be Wrong About iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Its Attractive Financial Prospects? (Simply Wall St.)
Nov-22-22 07:00AM	iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) -5.98%
Nov-10-22 07:55PM	ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates (Zacks) +11.14%
04:01PM	iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-04-22 05:46PM	Top Biotech Stocks for Q4 2022 (Investopedia)
Nov-02-22 10:00AM	ITeos Therapeutics, Inc. (ITOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-18-22 08:36AM	Shareholders in iTeos Therapeutics (NASDAQ:ITOS) are in the red if they invested a year ago (Simply Wall St.)
Aug-12-22 06:16AM	iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.) +7.00%
Aug-10-22 05:25PM	ITeos Therapeutics, Inc. (ITOS) Q2 Earnings and Revenues Lag Estimates (Zacks) -12.51%
04:01PM	iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Aug-02-22 07:00AM	iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire)

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Detheux Michel	Chief Executive Officer	Jun 10 '25	Option Exercise	4.30	137,910	593,013	94,027	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 09 '25	Option Exercise	4.30	43,882	188,693	43,882	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 10 '25	Option Exercise	4.30	26,400	113,520	153,903	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 09 '25	Option Exercise	4.30	8,400	36,120	144,303	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 09 '25	Sale	10.03	43,882	440,136	0	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 10 '25	Sale	10.02	43,883	439,708	0	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 09 '25	Sale	10.03	8,400	84,252	135,903	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 10 '25	Sale	10.02	8,400	84,168	135,903	Jun 11 09:01 PM
Detheux Michel	Officer	Jun 10 '25	Proposed Sale	10.02	52,283	523,876		Jun 10 04:19 PM
Detheux Michel	Officer	Jun 09 '25	Proposed Sale	10.17	52,282	531,708		Jun 09 04:12 PM
Detheux Michel	Chief Executive Officer	Jun 04 '25	Option Exercise	4.30	43,883	188,697	43,883	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 06 '25	Option Exercise	4.30	43,882	188,693	43,882	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 05 '25	Option Exercise	4.30	43,882	188,693	43,882	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 05 '25	Option Exercise	4.30	8,400	36,120	144,303	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 04 '25	Option Exercise	4.30	8,400	36,120	144,303	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 06 '25	Option Exercise	4.30	8,400	36,120	144,303	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 06 '25	Sale	10.21	43,882	448,035	0	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 05 '25	Sale	10.15	43,882	445,402	0	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 04 '25	Sale	10.10	43,883	443,218	0	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 06 '25	Sale	10.21	8,400	85,764	135,903	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 05 '25	Sale	10.15	8,400	85,260	135,903	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 04 '25	Sale	10.10	8,400	84,840	135,903	Jun 06 09:03 PM
Hallal David	Director	Jun 06 '25	Option Exercise	4.30	38,228	164,380	38,228	Jun 06 09:03 PM
Hallal David	Director	Jun 04 '25	Option Exercise	4.30	38,227	164,376	38,227	Jun 06 09:03 PM
Hallal David	Director	Jun 05 '25	Option Exercise	4.30	38,227	164,376	38,227	Jun 06 09:03 PM
Hallal David	Director	Jun 06 '25	Sale	10.24	38,228	391,455	0	Jun 06 09:03 PM
Hallal David	Director	Jun 05 '25	Sale	10.15	38,227	388,004	0	Jun 06 09:03 PM
Hallal David	Director	Jun 04 '25	Sale	10.07	38,227	384,946	0	Jun 06 09:03 PM
Detheux Michel	Officer	Jun 06 '25	Proposed Sale	10.19	52,282	532,754		Jun 06 04:11 PM
DAVID L HALLAL	Director	Jun 06 '25	Proposed Sale	10.24	38,228	391,489		Jun 06 04:09 PM
DAVID L HALLAL	Director	Jun 05 '25	Proposed Sale	10.15	38,227	388,103		Jun 05 04:27 PM
Detheux Michel	Officer	Jun 05 '25	Proposed Sale	10.22	52,282	534,322		Jun 05 04:10 PM
Detheux Michel	Officer	Jun 04 '25	Proposed Sale	10.06	52,283	525,967		Jun 04 04:03 PM
DAVID L HALLAL	Director	Jun 04 '25	Proposed Sale	10.07	38,227	384,782		Jun 04 04:03 PM
EcoR1 Capital, LLC	10% Owner	May 15 '25	Buy	8.00	3,300,000	26,400,000	10,688,978	May 16 06:52 PM
EcoR1 Capital, LLC	10% Owner	May 14 '25	Buy	7.41	1,658,978	12,285,562	7,388,978	May 16 06:52 PM
GADICKE ANSBERT	Former 10% Owner	May 13 '25	Sale	8.06	1,031,931	8,317,364	3,452,797	May 15 05:34 PM
MPM BIOVENTURES 2018, L.P.	Former 10% Owner	May 13 '25	Sale	8.06	630,191	5,079,339	2,108,594	May 15 05:33 PM
MPM BioVentures 2014, L.P.	Former 10% Owner	May 13 '25	Sale	8.06	630,191	5,079,339	2,108,594	May 15 05:32 PM
Van Hauwermeiren Timothy	Director	May 13 '25	Option Exercise	4.30	22,346	96,088	22,346	May 14 08:00 PM
Gall Matthew	Chief Financial Officer	Nov 19 '24	Buy	7.73	5,000	38,635	65,429	Nov 19 07:59 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ITOS

ITeos Therapeutics Inc

Upgrade your FINVIZ experience